Showing 7031-7040 of 8837 results for "".
- Survey Highlights Room for Improvement in AK Awarenesshttps://practicaldermatology.com/news/survey-highlights-room-for-improvement-in-ak-awareness/2461746/As many as 85% of people are unaware of actinic keratosis (AK), according to a new survey from Almirall. The survey of more than 2,500 participants over the age or 35 aimed to understand the level of knowledge about AK and skin health habits within the general population of Spain, Germa
- Epigenetic Mechanisms Activated by GHK-Cu Increase Skin Collagen Densityhttps://practicaldermatology.com/news/epigenetic-mechanisms-activated-by-ghk-cu-increase-skin-collagen-density/2461744/Epigenetic mechanisms activated by GHK-Cu may increase skin collagen density, new research suggests. The naturally occurring peptide GHK-Cu (GHK from glycyl-L-histidyl-L-lysine bound to a copper ion), which affects
- Melanoma Metastasis Discovery: Skin Cancer Rewires Energy Systems to Spreadhttps://practicaldermatology.com/news/melanoma-metastasis-discovery-skin-cancer-rewires-energy-systems-to-spread/2461743/Melanoma skin cancer cells may rewire their internal power systems to drive their spread to other parts of the body, a new study suggests. The research, led by investigators at Barts Cancer Institute, Queen Mary Unive
- Wayne State University Dermatology Resident Wins Svider Memorial Scholarship Awardhttps://practicaldermatology.com/news/wayne-state-university-dermatology-resident-wins-svider-memorial-scholarship-award/2461737/Kayla St. Claire, M.D., M.B.A., a Wayne State University School of Medicine dermatology resident, has won the Peter Svider Memorial Resident Scholarship Award. The award is presented annually to a graduating resident or fellow in any graduate medical education program in recognition of
- Orlucent Receives FDA Breakthrough Device Designation for Handheld Mole Imaging Systemhttps://practicaldermatology.com/news/orlucent-receives-fda-breakthrough-device-designation-for-handheld-mole-imaging-system/2461733/The U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for Orlucent’s Skin Fluorescence Imaging System. The Orlucent system is a handheld point-of-care molecular-based imaging system designed to noninvasively identify and clinically assess the pres
- SCALE News: Optimize Your Results with Radiofrequency Microneedlinghttps://practicaldermatology.com/news/radiofrequency-microneedling-optimize-your-results-1/2461731/For optimal results when treating patients with radiofrequency (RF) microneedling, anecdotal and personal experience guide Elizabeth L. Tanzi, MD, as there are “no significant comparison studies to date” on the
- EltaMD Teams Up With Bravo's Andy Cohen for Skin Cancer Awarenesshttps://practicaldermatology.com/news/eltamd-teams-up-with-bravos-andy-cohen-for-skin-cancer-awareness/2461729/EltaMD has partnered with Andy Cohen and the Melanoma Research Foundation on a social campaign aimed to ignite dialogue surrounding skin cancer, while educating consumers on the importance of skin checks for National Skin Cancer Awareness Month. As part of this initiative, and to encour
- AI In Action: Machine Learning Algorithms May Aid Diagnosis and Treatment of ADhttps://practicaldermatology.com/news/ai-in-action-machine-learning-algorithms-may-aid-diagnosis-and-treatment-of-ad/2461726/Researchers have developed six relatively stable and reliable diagnosis and efficacy evaluation prediction models for atopic dermatitis (AD) based on a machine learning algorithm. Songjiang Wu, a PhD candidate in dermatology from Third Xiangya Hospital at the Central South University in
- AOBiome’s B244 Eases Eczema Symptoms, Helps Tame Itchhttps://practicaldermatology.com/news/aobiomes-b244-eases-eczema-symptoms-helps-tame-itch/2461723/AOBiome Therapeutics, Inc.’s B244 treatment demonstrated significant improvements in eczema severity and itch reduction The Phase 2b clinical data is published in
- Oral IL-23 Receptor Antagonist Makes Waves in Tokyohttps://practicaldermatology.com/news/oral-il-23-receptor-antagonist-makes-waves-in-tokyo/2461716/Protagonist Therapeutics and Janssen Biotech, Inc.'s oral IL-23 receptor antagonist, JNJ-2113, performed well in Phase 1 and Pre-clinical Studies. JNJ-2113 is a macrocyclic peptide that binds to the IL-23 receptor with single digit picomolar affinity and demonstr